Fig. 8
PF-06747143 inhibits tumor burden and increases survival as a monotherapy or in combination with bendamustine, in a disseminated CLL tumor model. JVM-13-Luc CLL cells were implanted intravenously (1 × 106 cells) and allowed to spontaneously migrate and home in the bone marrow and lymph nodes for 19 days, when animals were randomized (n = 10/group). Animals were treated with IgG1 control or PF-06747143 antibodies at 10 mg/kg, subcutaneously, weekly, for six doses. Bendamustine was dosed at 30 mg/kg, intraperitoneally, on days 19 and 20, followed by another 2-day cycle 28 days later a Whole-body bioluminescence representative imaging showing bone marrow tumor burden on day 26. b Kaplan-Meier survival curve, using hind leg paralysis as endpoint